Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-09-26 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from a company's extraordinary shareholders meeting held on September 26, 2025. It details the meeting attendance, voting results on various proposals including appointment of the audit firm, changes in governance, and capital registration. It includes legal opinions confirming the validity of the meeting and resolutions. The document is an official announcement of the voting results from a shareholders meeting, not the meeting materials or the full report itself. The length is relatively short (2225 characters), and it focuses on the voting outcomes and legal validation. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-09-26 Chinese
奥锐特药业股份有限公司关于职工代表大会决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding resolutions passed at a company's employee representative meeting, specifically about the removal of a supervisory board member and the election of an employee representative director. It includes voting results and biographical details of the elected director. There are no financial statements, earnings data, or detailed financial analysis. The document is a formal announcement of board/management changes rather than a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management changes, not a report publication or regulatory filing.
2025-09-26 Chinese
奥锐特药业股份有限公司关于变更持续督导保荐代表人的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a convertible bond issuance project by 奥锐特药业股份有限公司. It details the replacement of a sponsor representative due to work changes and confirms that the change does not affect previously issued opinions or documents. There is no financial data, report, or detailed analysis included. The document is a regulatory announcement about management of a financing project, specifically about the sponsor representative change, which fits best under Capital/Financing Update (CAP). The document length is short and it is not a report or a certification, so it is not RNS or RPA. Therefore, the classification is CAP with high confidence.
2025-09-18 Chinese
奥锐特药业股份有限公司关于公司董事离任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, detailing the departure of a non-independent director, the reasons for resignation, and the impact on the company's board. It does not contain financial data, audit information, or report content. It specifically relates to changes in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming this classification.
2025-09-18 Chinese
奥锐特药业股份有限公司2025年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2025 年第一次临时股东大会 会议资料' which translates to '2025 First Extraordinary General Meeting (EGM) Meeting Materials'. It contains detailed agenda items for the meeting, including proposals on appointing the 2025 audit firm, canceling the supervisory board, capital changes, and amendments to the company charter. The document includes meeting procedures, voting instructions, and detailed explanations of the proposals to be voted on. It is a comprehensive set of materials prepared for the shareholders to review before or during the EGM. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during general meetings. Although it is an extraordinary meeting, the category AGM-R applies to both annual and extraordinary general meeting materials. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or a brief notice. Therefore, the correct classification is AGM Information (AGM-R).
2025-09-18 Chinese
奥锐特药业股份有限公司首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period, shareholder commitments, and changes in the company's total share capital. It references regulatory approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document is not a full financial report, earnings release, or management discussion but rather a formal notice about share listing and circulation. It fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and capital changes without substantive financial statements or detailed financial analysis. The document length is under 5,000 characters, and it is a formal announcement rather than a report itself.
2025-09-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.